Cost‐Effectiveness of NT ‐ proBNP –Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank
Authors' conclusion
Using NT-proBNP to prioritise use of cardioprotective treatment on top of standard of care to reduce the risk of progression to HF in Chinese patients with T2D is cost-effective
Study context
- Population
- Chinese adults with T2D; transition probabilities from the Hong Kong Diabetes Biobank (2014–2019)
- Exposure
- NT-proBNP-guided cardiovascular screening vs standard of care
- Outcome
- Cost-effectiveness (ICER per QALY)
- Follow-up
- Lifetime horizon
Methodological detailsMarkov cohort model, four-state Markov cohort model, payer's perspective, lifetime horizon, annual cycles, 2023 costs
- Markov cohort model
- Four-state Markov cohort model
- Payer's perspective
- Lifetime horizon
- Annual cycles
- 2023 costs
Main finding
As reported in the abstract
- NT-proBNP 400 pg/mL · cost-saving
- ICER -USD $6558 per quality-adjusted life years (QALY)
- NT-proBNP 400 pg/mL
- incremental cost -USD $846
- NT-proBNP 400 pg/mL
- incremental QALYs 0.129 QALY
- NT-proBNP 125 pg/mL · cost-effective
- ICER USD $29 290 per QALY
Observational data: associations, not effects.
Further findings
| Outcome | NT-proBNP 400 pg/mL | NT-proBNP 125 pg/mL |
|---|---|---|
| Probabilistic sensitivity analysis: probability of dominance at Hong Kong's WTP thresholds (USD$50,889-152,667) | 100% | 98% |
Deterministic sensitivity analysis
- NT-proBNP specificity was the key driver of incremental cost-effectiveness ratios (ICERs) in both cut-offs
Original publication
Cost‐Effectiveness of NT ‐ proBNP –Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank. Diabetes Obes Metab. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →